Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–16 of 16 results
Advanced filters: Author: Amanda Micklus Clear advanced filters

    • Patricia Giglio
    • Amanda Micklus
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 24, P: 86-87

    • Patricia Giglio
    • Amanda Micklus
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 23, P: 101-102

    • Patricia Giglio
    • Amanda Micklus
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 22, P: 92-93

    • Amanda Micklus
    • Patricia Giglio
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 21, P: 93-94

    • Patricia Giglio
    • Amanda Micklus
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 20, P: 95-96

    • Amanda Micklus
    • Patricia Giglio
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 19, P: 87-88

    • Amanda Micklus
    • Steven Muntner
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 18, P: 93-94

  • This article analyses merger and acquisition (M&A) activity and partnerships in the biopharma industry in 2017, highlighting trends and major deals.

    • Amanda Micklus
    • Steven Muntner
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 17, P: 91-92

  • Highlights of deal-making activity in 2014 include divestitures and asset swaps among large pharmaceutical companies, and a slew of cancer immunotherapy alliances.

    • Amanda Micklus
    • Steven Muntner
    News
    Nature Reviews Drug Discovery
    Volume: 14, P: 84-85

  • This article analyses merger and acquisition (M&A) activity and partnerships in the biopharma industry in 2016, highlighting trends and major deals.

    • Amanda Micklus
    • Steven Muntner
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 16, P: 161-162

  • Last year saw an uptick in medtech mergers and acquisitions values, whereas financing declined. This year is bringing new opportunities and challenges for the field as it responds to the demands of the coronavirus.

    • Maureen Riordan
    • Amanda Micklus
    News
    Biopharma Dealmakers

  • Plentiful acquisitions, increased financing and pioneering digital health approvals all shaped the medtech industry in 2018. With nontraditional players such as Apple and Google engaging in the field, the industry looks set to evolve further.

    • Amanda Micklus
    • Maureen Riordan
    News
    Biopharma Dealmakers

  • Although dealmaking in the medtech industry slowed in 2017, political developments and innovations in areas such as digital health technologies could fuel greater activity in 2018.

    • Amanda Micklus
    • Maureen Riordan
    News
    Biopharma Dealmakers

  • Although the volume and value of merger and acquisition (M&A) deals in the medtech industry both increased in 2016 compared with 2015, M&A activity declined during the year, reflecting the challenges that the industry faces.

    • Amanda Micklus
    • Maureen Riordan
    News
    Biopharma Dealmakers